5240752025-10-012025-12-315240752025-04-012025-12-315240752025-10-012025-12-31in-capmkt:OtherExpenses1Member5240752025-04-012025-12-31in-capmkt:OtherExpenses1Member5240752025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15240752025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524075ALBERTDAVDNOTLISTEDINE155C01010ALBERT DAVID LIMITEDMain BoardEquity2025-04-012026-03-312026-02-112026-02-02INRLakhsQuarterlyThird quarterSingle segmentpharmacueticals2026-02-1111:30:002026-02-1116:00:00Not applicablefalsefalseNIL2025-10-012025-12-31UnauditedStandalone8992690001239930001023262000167492000145795000-3495600023898300089770002423500027371100082423700019902500001990250003105100014936000459870000153038000000015303800014014000167052000570720001026.8126.810026.8126.81 1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 11th February, 2026.The Limited Review for the quarter and nine months ended 31st December, 2025 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LO&DR) Regulations, 2015. <BR> <BR> 2. The Ministry of Labour and Employment has implemented the New Labour Codes (Wages, Social Security, Industrial Relations, and Occupational Safety, Health & Working Conditions), effective 21 November 2025, replacing 29 existing labour laws. Based on available information and ICAI guidance, the Company has assessed the impact as not material and reflected it in its financial results for the quarter and nine months ended 31 December 2025. The Company continues to monitor the finalisation of rules by the Central and State Governments and clarifications from the Government on other aspects of the New Labour Codes and will account for such developments as needed <BR> <BR> 3. The Statutory Auditors of the Company have issued an unmodified review report on the Unaudited Financial Results for the quarter and nine months ended 31st December, 2025. <BR> <BR> 4. The Company is engaged in the manufacturing of pharmaceuticals and has only one reportable segment in accordance with Ind AS-108 "Operating Segments". <BR> <BR> 5. Figures for the previous periods are regrouped to conform to the figures of the current period as and when required in limited context of format of financial results and disclosures thereon specified by SEBI. <BR> 2025-04-012025-12-31UnauditedStandalone24773470003229170002800264000419841000349448000683720007940320002203100070404000818549000254267700025758700002575870003105100027139000581900000199397000000019939700010325000209722000570720001034.9434.940034.9434.94Other expenses273711000Other expenses818549000Items that will not be reclassified to profit or loss1897700018977000Items that will not be reclassified to profit or loss140470001404700049630003722000001401400010325000